Cargando…
CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
To analyze and compare the effects of intravitreal brolucizumab versus aflibercept on systemic vascular endothelial growth factor (VEGF)-A levels in patients with neovascular age-related macular degeneration. METHODS: In this prospective interventional case series study, brolucizumab (6.0 mg/50 µL)...
Autores principales: | Angermann, Reinhard, Huber, Anna Lena, Nowosielski, Yvonne, Salcher, Stefan, Gasser, Thomas, Seifarth, Christof, Kralinger, Martina T., Zehetner, Claus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Retina
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852685/ https://www.ncbi.nlm.nih.gov/pubmed/34731094 http://dx.doi.org/10.1097/IAE.0000000000003344 |
Ejemplares similares
-
Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration
por: Huber, Anna Lena, et al.
Publicado: (2021) -
Systemic counterregulatory response of angiopoietin‐2 after aflibercept therapy for nAMD: a potential escape mechanism
por: Angermann, Reinhard, et al.
Publicado: (2020) -
Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation
por: Angermann, Reinhard, et al.
Publicado: (2022) -
The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48‐month follow‐up study
por: Angermann, Reinhard, et al.
Publicado: (2021) -
The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)